An Extension Trial to Investigate Long-Term Treatment With Transdermal Rotigotine in Idiopathic Restless Legs Syndrome
Restless Legs Syndrome
About this trial
This is an interventional treatment trial for Restless Legs Syndrome focused on measuring IDIOPATHIC RESTLESS LEGS SYNDROME
Eligibility Criteria
Inclusion Criteria: Idiopathic restless legs syndrome Exclusion Criteria: Subject has an ongoing serious adverse event from SP792 that is assessed to be related to the trial medication by the investigator and/or the sponsor. Subject is pregnant, nursing, or is a woman of child-bearing potential who is not surgically sterile, 2 years postmenopausal, or does not consistently use 2 combined effective methods of contraception, including at least 1 barrier method, unless sexually abstinent. Subject has any medical or psychiatric condition that, in the opinion of the investigator, can jeopardize or would compromise the subject's ability to participate in this trial.
Sites / Locations
- Schwarz
Arms of the Study
Arm 1
Experimental
1
Up to 6.75 mg/day (optimal dosing)